9-AzSiaNAc
| Product Name | 9-AzSiaNAc |
|---|---|
| Alternate Names | - Carbohydrates, Carbohydrates of - |
| CAT No. | CS-O-51111 |
| CAS No. | 160555-88-4 |
| Category | Carbohydrates |
| Stock | Enquire |
| Mol. Wt. | 334.28 g/mol |
| Mol. For. | C11H18N4O8 |
| Hazardous | This is not a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | - |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Get an Instant Quote
Related Compounds
GM2Cer d18:1/16:0 (GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | ALewis B (ALe b ) | GM2sph d20:1 (GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbSphingolipids) | GM1asph d20:1 (Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbSphingolipids) | Blood type trisaccharide A | GM1bCer d18:1/8:0 (Neu5Aca2,3Galb1,3GalNAcb1,4Galb1,4GlcbCeramide) | FucGM1Cer d18:1/18:0 ((Fuca1,2)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | GD1aCer d18:1/20:0 ((Neu5Aca2,3)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | FucGM1Cer d20:1/20:0 ((Fuca1,2)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | GT1cCer d20:1/20:0 (Galb1,3GalNAcb1,4(Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | Lewis B (Leb ) | GD2Cer d18:1/16:0 (GalNAcb1,4(Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | GlcNAcb1, 3Galb1, 4(Fuca1, 3)GlcNAc | FucGM1Cer d20:1/16:0 ((Fuca1,2)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | Ac3 GlcNAcproN3 | FucGM1Cer d18:1/8:0 ((Fuca1,2)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | Galb1, 4GlcNAcb1, 3Galb1, 4GlcNAcb1, 3Galb1, 4GlcNAc | L-Rhamnulose | GT3Cer d18:1/24:1 (Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide) | GT1cCer d18:1/20:0 (Galb1,3GalNAcb1,4(Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | BPA-Neu5Gc | FucGM1Cer d20:1/8:0 ((Fuca1,2)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | GD3Cer d18:1/12:0 (Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide) | GD1aCer d18:1/18:0 ((Neu5Aca2,3)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | nLc4 | Neu5Aca2,3（HSO4 -6-)Galb1,4GlcNAc | GQ3Cer d20:1/18:0 (Neu5Aca2,8Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide) | Blood type trisaccharide H Type III/IV | GD3Cer d20:1/12:0 (Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide) | GT2Cer d20:1/20:0 (GalNAcb1,4(Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | FucGM1sph d20:1 ((Fuca1,2)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbSphingolipids) | NeuAca2, 6Galb1, 4GlcNAc | P(Galb1,3Gala1,4Galb1,4GlcbR) | GM1bCer d18:1/12:0 (Neu5Aca2,3Galb1,3GalNAcb1,4Galb1,4GlcbCeramide) | FucGM1Cer d18:1/12:0 ((Fuca1,2)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | GD1bsph d18:1 (Galb1,3GalNAcb1,4(Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbSphingolipids) | GD1bCer d18:1/20:0 (Galb1,3GalNAcb1,4(Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | LS-tetrasaccharide c | P1(Gala1,4Galb1,4GlcNAcb1,3Galb1,4GlcbR) | Bortezomib D-mannitol | GD2Cer d18:1/18:0-Biotin (GalNAcb1,4(Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide-Biotin) | GM3Cer d20:1/18:0 (Neu5Aca2,3Galb1,4GlcbCeramide) | Trifucosyllacto-N-hexaose | GD3Cer d18:1/24:1 (Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide) | Lactose PEG-NH2 | Glucoerucin potassium salt | GT1cCer d18:1/16:0 (Galb1,3GalNAcb1,4(Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | GT3Cer d20:1/8:0 (Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide) | GM1bCer d20:1/18:0 (Neu5Aca2,3Galb1,3GalNAcb1,4Galb1,4GlcbCeramide) | GT3sph d18:1 (Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbSphingolipids) | Blood type trisaccharide H Type VI (2'FL) | GT3Cer d18:1/20:0 (Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide) | GD1bCer d18:1/18:0 (Galb1,3GalNAcb1,4(Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | D-Fructose-1-phosphate disodium salt | A-Antigen-Cer d18:1/18:0-Biotin (GalNAca1,3(Fuca1,2)Galb1,4GlcbCeramide-Biotin) | GM1bCer d18:1/20:0 (Neu5Aca2,3Galb1,3GalNAcb1,4Galb1,4GlcbCeramide) | D-galactosyl-α-1,1' N-palmitoyl-D-erythro-sphingosine | GM2 | GT3Cer d20:1/12:0 (Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide) | GT3Cer d18:1/18:0-Biotin (Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide-Biotin) | GalNAcproN3 | GD1bCer d18:1/24:1 (Galb1,3GalNAcb1,4(Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | GM1bCer d20:1/8:0 (Neu5Aca2,3Galb1,3GalNAcb1,4Galb1,4GlcbCeramide) | Neu5Gca2, 3Galb1, 4GlcNAc | Trehalulose | GM1aCer d18:1/8:0 (Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | Sialyl-Lc4 | GD1aCer d20:1/8:0 ((Neu5Aca2,3)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | GD3Cer d20:1/8:0 (Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide) | Ac4 ManNAc |